Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actilyse vs Saline for Occluded CVAD
NCT01958164Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2013
- Primary completion
- Apr 2014
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alteplase in central venous catheter occlusion (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Proportion of Patients With Restored CVAD Function at 120 Min After Administration of the First Dose of Study Medication. Started Sep 2013; status: completed.
02
Drugs
alteplase
03
Conditions
central venous catheter occlusion
Beyond the preview
Go deeper on NCT01958164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958164.